Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sideris Pet Pharmaceuticals LP has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner in 1 distinct art unit. The concentration in 1 art unit suggests a focused pharmaceutical review for the company's current patenting efforts. This structure provides a singular point of contact for the company's active prosecution, as there is no distribution across multiple officials or administrative groups at the USPTO.
MITCHELL, EDWIN COLEMAN is the busiest examiner, managing 1 pending office action. This 1 action represents the entire pending workload for the company. The focus on 1 art unit indicates that the company's filings are facing a singular examination path. For a practitioner, the progress of this 1 action is the sole focus of the company's current prosecution strategy. The alignment of 1 examiner and 1 art unit ensures that the technical arguments are reviewed by a single official within a specialized administrative group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18526027 | Method and Product for the Identification of Diseased Animals | MITCHELL, EDWIN COLEMAN | 35d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18526027 | Method and Product for the Identification of Diseased Animals | MITCHELL, EDWIN COLEMAN | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18526027 | Method and Product for the Identification of Diseased Animals | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | 35d overdue | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSideris Pet Pharmaceuticals LP has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Edwin Coleman Mitchell has the most, with 1 of Sideris Pet Pharmaceuticals LP's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.